“…Currently, similarities and disparities of the disorders are discussed. 1,2 In this case, absence of interface dermatitis with histopathological evaluation excluded the diagnoses of LLP and LLPP. EDP is characterized by ash-colored macules or patches.…”
Section: Squamous Cell Carcinomas Arising From Relapsing Blaschkolinementioning
confidence: 95%
“…
disrupts the PD-1/programmed cell-death ligand 1 (PD-L1) pathway. [2][3][4] We describe herein the first case of LPP in a patient with metastatic non-small-cell lung cancer (NSCLC) treated with the anti-PD-L1 agent atezolizumab.A 76-year-old Japanese woman presented with a pruritic eruption on her extremities and back. She had developed squamous cell carcinoma of the lung with liver metastasis (T1cN2M1b, stage IVA) and was treated with atezolizumab (1200 mg every 3 weeks) for six cycles over 4 months.
…”
mentioning
confidence: 99%
“…disrupts the PD-1/programmed cell-death ligand 1 (PD-L1) pathway. [2][3][4] We describe herein the first case of LPP in a patient with metastatic non-small-cell lung cancer (NSCLC) treated with the anti-PD-L1 agent atezolizumab.…”
“…Currently, similarities and disparities of the disorders are discussed. 1,2 In this case, absence of interface dermatitis with histopathological evaluation excluded the diagnoses of LLP and LLPP. EDP is characterized by ash-colored macules or patches.…”
Section: Squamous Cell Carcinomas Arising From Relapsing Blaschkolinementioning
confidence: 95%
“…
disrupts the PD-1/programmed cell-death ligand 1 (PD-L1) pathway. [2][3][4] We describe herein the first case of LPP in a patient with metastatic non-small-cell lung cancer (NSCLC) treated with the anti-PD-L1 agent atezolizumab.A 76-year-old Japanese woman presented with a pruritic eruption on her extremities and back. She had developed squamous cell carcinoma of the lung with liver metastasis (T1cN2M1b, stage IVA) and was treated with atezolizumab (1200 mg every 3 weeks) for six cycles over 4 months.
…”
mentioning
confidence: 99%
“…disrupts the PD-1/programmed cell-death ligand 1 (PD-L1) pathway. [2][3][4] We describe herein the first case of LPP in a patient with metastatic non-small-cell lung cancer (NSCLC) treated with the anti-PD-L1 agent atezolizumab.…”
“…disrupts the PD-1/programmed cell-death ligand 1 (PD-L1) pathway. [2][3][4] We describe herein the first case of LPP in a patient with metastatic non-small-cell lung cancer (NSCLC) treated with the anti-PD-L1 agent atezolizumab. A 76-year-old Japanese woman presented with a pruritic eruption on her extremities and back.…”
mentioning
confidence: 99%
“…On the other hand, reports of LPP associated with anti-PD-1/PD-L1 agents are rare, with a total of four cases including ours. [2][3][4] That is because some cases of LPP induced by anti-PD-1/PD-L1 agents might have been interpreted as lichen planus or bullous pemphigoid due to their clinicopathological and/or serological similarities to LPP. Although the elevated serum anti-BP180 antibody level in our case was not pronounced, it was normalized in correlation with the improvement of the skin lesion.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.